MISSISSAUGA, ON – Toronto’s Princess Margaret Cancer Centre has joined Hoffmann-La Roche Limited’s (Roche Canada) global cancer immunotherapy Centres of Research Excellence (imCORE) Network.
The network brings together leading scientific and clinical experts in cancer immunotherapy to collaborate on the investigation and development of promising new treatment approaches for the disease. The goal of the imCORE Network is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries in cancer immunotherapy and to aggregate, as well as share data to help accelerate cancer research.
According to the Canadian Cancer Society, cancer is the leading cause of death in Canada and is responsible for 30 per cent of all deaths in the country. In fact, two out of five Canadians (45 per cent of men and 42 per cent of women) are expected to develop cancer during their lifetimes.
“Cancer is a complex disease, and one that poses a significant burden across the world,” said Ronnie Miller, president and CEO, Roche Canada. “As a research-driven organization, Roche is proud to have the Princess Margaret Cancer Centre join the imCORE Network to help us better understand immune biology and cancer, and to ultimately improve treatment options, as well as outcomes for patients. We believe that by working as a truly global cancer research team, we can help transform the fight against cancer.”
The imCORE Network is comprised of 21 academic centres, inclusive of Princess Margaret Cancer Centre, from nine countries across the globe, working together to access and share technology, data and expertise to advance science.
“The imCORE Network provides a great opportunity for academic centres like ours to collaborate and explore new concepts, both in the laboratory and in the clinic,” said Dr. Lillian Siu, medical oncologist at Princess Margaret Cancer Centre and site lead for the imCORE Network. “This type of collective learning is exactly what is needed to make important progress in a field as fast-moving as cancer immunotherapy.”
As a part of a global announcement regarding the launch of the imCORE Network, Roche is investing up to 100 million Swiss Francs (more than $130 million Canadian dollars) to support basic and clinical research collaborations related to cancer immunotherapy. The investment is incremental to Roche’s on-going research and development of investigational medicines and treatment approaches in the field of cancer immunotherapy.
Dr. Siu discusses the imCORE Network in the video below.